Close

Inverness Medical Innovations Plans Move to NYSE

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

WHO Supplies Medical Equipment for Post-Marburg...

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK...

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences...

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized...

The Human Medicines Regulations 2025, which came into force...
Inverness Medical Innovations, Inc., a leading provider of near-patient diagnostics, monitoring and health management solutions, announced that it intends to move the trading of its listed securities to the New York Stock Exchange (NYSE).  The Company has filed its listing application with NYSE and currently expects its listings on NYSE to commence on January 6, 2009.  Until that time the Company’s shares will continue to trade on Alternext (formerly the American Stock Exchange).  The Company’s Common Stock will continue to trade under the symbol, “IMA” and its Series B Convertible Perpetual Preferred Stock will continue to trade under the symbol, “IMA.PR.B”.

Inverness Medical Innovations, Inc., a leading provider of near-patient diagnostics, monitoring and health management solutions, announced that it intends to move the trading of its listed securities to the New York Stock Exchange (NYSE).  The Company has filed its listing application with NYSE and currently expects its listings on NYSE to commence on January 6, 2009.  Until that time the Company’s shares will continue to trade on Alternext (formerly the American Stock Exchange).  The Company’s Common Stock will continue to trade under the symbol, “IMA” and its Series B Convertible Perpetual Preferred Stock will continue to trade under the symbol, “IMA.PR.B”.

Ron Zwanziger, Inverness’ Chairman, Chief Executive Officer and President said, We are proud to be able to move our listings over to the New York Stock Exchange and offer our shareholders the increased liquidity and visibility available through this premier exchange. We look forward to a long and successful relationship with NYSE.

Duncan Niederauer, NYSE Euronext CEO, We are pleased to welcome Inverness, a leader in medical diagnostics products and health management, to our family of listed companies. Inverness recognizes the value and benefits of listing on the NYSE, and we look forward to serving the company and its shareholders
 

Latest stories

Related stories

WHO Supplies Medical Equipment for Post-Marburg Virus Heal

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back